Review
Copyright ©The Author(s) 2022.
World J Transplant. Mar 18, 2022; 12(3): 27-41
Published online Mar 18, 2022. doi: 10.5500/wjt.v12.i3.27
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Block of co-stimulation with Belatacept. APC: Antigen presenting cell; T eff: T effector; T reg: Regulatory T cells; PDL1: Programmed cell death receptor ligand 1; CTLA4: Cytotoxic T-lymphocyte-associated antigen 4.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Block of co-stimulation with anti CD28. APC: Antigen presenting cell; T eff: T effector; T reg: Regulatory T cells; PDL1: Programmed cell death receptor ligand 1; CTLA4: Cytotoxic T-lymphocyte-associated antigen 4.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 CTOT24 trial.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Drugs acting at different levels to control the antibody formation. BLyS: B Lymphocyte stimulating factor; mAb: Monoclonal antibody; C1-INH: C1 inhibitors; NK: Natural killer; Cp: Complement; FcyR: FcyReceptor; MAC: Membrane attacking complex; MHC: Major histocompatibility complex; IL: Interleukin.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Principal drugs affecting complement. C1-INH: C1 inhibitor; MAC: Membrane attacking complex.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Cleaving intact immunoglobulin G by imlifidase. CDC: Complement dependent cytotoxicity; ADCC: Antibody dependent cell cytotoxicity; F(ab): Fragment ab; Fc: Fragment c; Ides: Imlifidase; IgG: Immunoglobulin G.